Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda) and targeted therapies (e.g., Eisai’s Lenvima) are experiencing uptake. Some agents target specific biomarker-defined populations, such as MSI-H or dMMR, and others target all patients. The approval and uptake of these agents will result in a more-personalized approach to treating advanced endometrial carcinoma. Several agents are also being positioned for the untapped first-line setting (e.g., GSK/Tesaro’s dostarlimab, Karyopharm’s Xpovio, AstraZeneca’s Lynparza) and will contribute to robust market growth over the 2019-2029 forecast period.

Questions answered:

  • How large are the clinically and commercially relevant drug-treatable endometrial carcinoma populations, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as Keytruda and Lenvima, for endometrial carcinoma?
  • Which pipeline products are poised to become options for the treatment of endometrial carcinoma, and what sales / uptake will they secure?
  • What are the key drivers and constraints in the endometrial carcinoma market, and how will the major markets evolve over the ten-year forecast period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists.

Epidemiology: Diagnosed incident of endometrial carcinoma by country, disease stage, and risk status.

Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key endometrial cancer therapies through 2029, segmented by brands / biosimilars / generics, disease stage, and country.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select early-phase products.

Table of contents

  • Endometrial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
      • Key Findings
        • Endometrial Carcinoma Key Findings - March 2021
        • Market Outlook
          • Key Findings
            • Major-Market Share of Drug Classes for Endometrial Carcinoma: 2019
            • Major-Market Share of Drug Classes for Endometrial Carcinoma: 2029
            • Major-Market Sales of Key Therapies for Endometrial Carcinoma: 2019-2029
            • Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2019
            • Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2029
            • Positioning of Key Therapies in Endometrial Carcinoma in the United States: 2019-2029
            • Population Positioning of Therapies in Endometrial Carcinoma
            • SWOT Analysis
          • COVID-19: Areas of Potential Forecast Impact
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for Endometrial Carcinoma?
              • What Factors Are Constraining the Market for Endometrial Carcinoma?
            • Segment-Specific Trends
              • Patient Share Dynamics of Key Agents in Early-Stage Endometrial Carcinoma in the United States: 2019-2029
              • Patient-Share Dynamics of Key Agents in First-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
              • Patient-Share Dynamics of Key Agents in Second-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
              • Patient-Share Dynamics of Key Agents in Third-Line Advanced or Recurrent Endometrial Carcinoma in the United States: 2019-2029
          • Forecast
            • Market Forecast Assumptions
            • Market Forecast Dashboard
          • Etiology and Pathophysiology
            • Disease Overview
              • Disease Pathophysiology
                • Anatomy of the Uterus
                • Anatomy of the Uterus
                • Prognostic Biomarkers in Endometrial Cancer
                • Prognostic Biomarkers in Endometrial Cancer
              • Staging and Classification
                • Classification of Endometrial Cancer
                • AJCC Prognostic Stage Groups for Endometrial Cancer
                • AJCC TNM and FIGO Surgical Staging Systems for Endometrial Cancer
              • Key Pathways and Drug Targets
                • Key Pathways and Drug Targets in Endometrial Cancer
                • Immune Checkpoint Inhibitors and Modulators
                • PARP Inhibition: Mechanism of Action
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incidence of Endometrial Carcinoma
                  • Diagnosed Incident Cases of Endometrial Carcinoma: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Stage Distribution of Endometrial Carcinoma
                  • Diagnosed Incident Cases of Endometrial Carcinoma by Stage Distribution: 2019-2029
                  • Definition
                  • Methods
                  • Sources Used for Recurrent Incidence of Endometrial Carcinoma
                  • Recurrent Incident Cases of Endometrial Carcinoma: 2019-2029
                  • Endometrial Carcinoma Patient Flow
                  • Drug-Treatable Cases of Endometrial Carcinoma: 2019-2029
                  • Drug-Treated Cases of Endometrial Carcinoma: 2019-2029
              • Current Treatment
                • Key Findings
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Endometrial Carcinoma
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Endometrial Carcinoma
                    • Current Treatments Used for Endometrial Carcinoma
                    • Market Events Impacting the Use of Key Current Therapies for Endometrial Carcinoma
                    • Keytruda
                    • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Endometrial Carcinoma
                    • Ongoing Clinical Development of Keytruda
                    • Key Ongoing Clinical Trials of Keytruda in the Treatment of Endometrial Carcinoma
                    • Expert Insight: Keytruda
                    • Jemperli
                    • Key Results From Select Clinical Trials Investigating Jemperli for the Treatment of Endometrial Carcinoma
                    • Ongoing Clinical Development of Jemperli
                    • Key Ongoing Trials of Jemperli in the Treatment of Endometrial Carcinoma
                    • Expert Insight: Jemperli
                    • Lenvima
                    • Ongoing Clinical Development of Lenvima
                    • Expert Insight: Lenvima
                    • Hormonal Agents
                    • Expert Insight: Hormonal Agents
                  • Medical Practice
                    • Newly Diagnosed Early-Stage (Stage I-II) Endometrial Carcinoma
                    • First-Line Advanced or Recurrent Endometrial Carcinoma
                    • Second- and Later-Line Advanced or Metastatic Endometrial Carcinoma
                    • Country-Specific Endometrial Carcinoma Treatment Guidelines
                    • Patient Characteristics Influencing Drug Selection in Endometrial Carcinoma
                    • Treatment Decision Tree for Newly Diagnosed (Early-Stage) Endometrial Carcinoma: G7
                    • Treatment Decision Tree for Endometrial Carcinoma: United States
                    • Treatment Decision Tree for Endometrial Carcinoma: Europe
                    • Treatment Decision Tree for Endometrial Carcinoma: Japan
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Endometrial Carcinoma
                  • Top Unmet Needs in Endometrial Carcinoma: Current and Future Attainment
                  • Expert Insight: Unmet Need in Endometrial Carcinoma
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends in Endometrial Carcinoma
                  • Key Emerging Therapies
                    • Key Therapies in Development for Endometrial Carcinoma
                    • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Endometrial Carcinoma
                    • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Endometrial Carcinoma
                    • Key Ongoing Trials of Tecentriq in the Treatment of Endometrial Carcinoma
                    • Analysis of the Clinical Development Program for Tecentriq
                    • Expert Insight: Tecentriq
                    • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Endometrial Carcinoma
                    • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Endometrial Carcinoma
                    • Key Ongoing Trials of Imfinzi in the Treatment of Endometrial Carcinoma
                    • Analysis of the Clinical Development Program for Imfinzi
                    • Expert Insight: Imfinzi
                    • Expectations for Market Authorization and Sales Opportunity of Imfinzi in Endometrial Carcinoma
                    • Key Results from Select Clinical Trials Investigating Xpovio for the Treatment of Endometrial Carcinoma
                    • Key Ongoing Trials of Xpovio in the Treatment of Endometrial Carcinoma
                    • Analysis of the Clinical Development Program for Xpovio
                    • Expert Insight: Xpovio
                    • Expectations for Market Authorization and Sales Opportunity of Xpovio in Endometrial Carcinoma
                    • Analysis of the Clinical Development Program for Lynparza
                    • Expert Insight: Lynparza
                    • Expectations for Market Authorization and Sales Opportunity of Lynparza in Endometrial Carcinoma
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Early-Phase Development for Endometrial Cancer
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Endometrial Carcinoma: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Endometrial Carcinoma: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Endometrial Carcinoma: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Key Abbreviations Related to Endometrial Carcinoma
                  • Brands, Marketers, and Generic Availability of Key Therapies for Endometrial Carcinoma: by Market
                  • Endometrial Carcinoma Bibliography